A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.
about
Molecular Targeted Intervention for Pancreatic CancerLack of an association between angiotensin receptor blocker based therapy and increased risk of cancer: evidence from large observational studiesMarketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.Immunomodulatory effect of captopril and local irradiation on myeloid-derived suppressor cells.Role of pancreatic stellate cells in chemoresistance in pancreatic cancer.Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy.The use of angiotensin II receptor antagonists to increase the efficacy of radiotherapy in cancer treatment.Strategies for improving drug delivery: nanocarriers and microenvironmental priming.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer.Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
P2860
Q26798453-D95093EE-3508-4157-8057-112A64E45C7FQ28544725-87DAB902-3B12-49FA-8F04-820D25263B92Q35653603-190E6D85-3F01-4819-9907-978F13DFB431Q37250548-B3277B12-F426-4AC8-A475-0FD4FEC35538Q37343451-55B475B5-5C12-419E-8715-C42E70EEA1E0Q37705462-BA8A307F-FADC-4C64-A91F-3BD5AC84B66EQ37711653-3CF5D73B-B66C-42F0-8AAC-E7EE08A587EFQ38294600-402DAF3D-3B77-4FF9-BC37-6683A4C57144Q38968910-E64909AE-E74E-4E36-B5E9-D73F8C12A9B3Q39390859-9A42240F-F13D-408B-9E07-34F8AAD2174BQ40462627-6DC4E762-5677-4C3A-B8BA-565CAC773577Q42776799-AA7C90AC-D2AA-4894-855E-33C267B74CEFQ47863448-33A87BB8-EAC0-4CCF-BDAC-B56C126AE387Q58748151-3E030819-6053-4DCF-831A-42A41F17DDF6
P2860
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A multicenter phase II trial o ...... nced pancreatic cancer: GECA2.
@ast
A multicenter phase II trial o ...... nced pancreatic cancer: GECA2.
@en
type
label
A multicenter phase II trial o ...... nced pancreatic cancer: GECA2.
@ast
A multicenter phase II trial o ...... nced pancreatic cancer: GECA2.
@en
prefLabel
A multicenter phase II trial o ...... nced pancreatic cancer: GECA2.
@ast
A multicenter phase II trial o ...... nced pancreatic cancer: GECA2.
@en
P2093
P2860
P1476
A multicenter phase II trial o ...... anced pancreatic cancer: GECA2
@en
P2093
Hideaki Ijichi
Hirofumi Kogure
Hiroshi Yagioka
Hiroyuki Isayama
Keisuke Tateishi
Keisuke Yamamoto
Kenji Hirano
Koji Miyabayashi
Minoru Tada
Naminatsu Takahara
P2860
P2888
P304
P356
10.1007/S10637-013-9972-5
P577
2013-05-21T00:00:00Z
P6179
1028882535